This is an open-label, phase 2 study evaluating Entrectinib for the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/2/3, ROS1, or ALK gene rearrangements.
- Trial ID:
- Darren Sigal, M.D.
- Male or female, 18 years of age or older
- Pathology confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement. Tumor testing will be provided through the study.
- Current participation on another clinical trial
- Active gastrointestinal disease or other malabsorption syndromes that would reasonably impact drug absorption